Diffusion of Breast Cancer Risk Assessment in Primary Care

References

1. ↵
   Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2003. Bethesda (MD): National Cancer Institute, 2006.
3. ↵
   Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81: 1879–86.

   OpenUrlAbstract/FREE Full Text
4. ↵
   Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med 2000; 342: 564–71.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652–62.

   OpenUrlAbstract/FREE Full Text
6. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003; 95: 526–32.

   OpenUrlAbstract/FREE Full Text
7. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group [see comment]. J Clin Oncol 2004; 22: 1055–62.

   OpenUrlAbstract/FREE Full Text
8. ↵
   Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer [comment]. J Natl Cancer Inst 2001; 93: 334–5.

   OpenUrlFREE Full Text
9. ↵
   Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278: 1242–50.

   OpenUrlCrossRefPubMedWeb of Science
10. Couch F, DeShano M, Blackwood M, Weber B. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409–15.

    OpenUrlCrossRefPubMedWeb of Science
11. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16: 2417–25.

    OpenUrlAbstract
12. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: Implications for risk prediction. Cancer 1994; 73: 643–51.

    OpenUrlCrossRefPubMedWeb of Science
13. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62: 145–58.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21: 593–601.

    OpenUrlAbstract/FREE Full Text
15. ↵
    Gail M, Rimer B. Risk-based recommendations for mammographic screening for women in their forties [see comment]. J Clin Oncol 1998; 16: 3105–14.

    OpenUrlAbstract/FREE Full Text
16. ↵
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005; 143: 355–61.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    Haas J, Kaplan C, Gregorich S, Perez-Stable E, Des Jarlais G. Do physicians tailor their recommendations for breast cancer risk reduction based on patient risk? J Gen Intern Med 2004; 19: 302–8.

    OpenUrlCrossRefPubMed
19. ↵
    Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med 2005; 41: 7–15.

    OpenUrlCrossRefPubMed
20. ↵
    Green L, Eriksen M, Schor E. Preventive practices by physicians: behavioral determinants and potential interventions. Am J Prev Med 1988; 4: 101–7.

    OpenUrlPubMed
21. Green L, Kreuter M. Health promotion planning. 2nd ed. Mountain View: Mayfield Publishing Co; 1991.
22. ↵
    Armstrong K, Quistberg DA, Micco E, Domchek S, Guerra C. Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med 2006; (166): 2260–5.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Wideroff L, Freedman AN, Olson L, et al. Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev 2003; 12: 295–303.

    OpenUrlAbstract/FREE Full Text
24. ↵
    Rogers E. Diffusion of innovations. New York: Free Press; 1995.
25. Greenberg MR. The diffusion of public health innovations. Am J Public Health 2006; 96: 209–10.

    OpenUrlCrossRefPubMedWeb of Science
26. Rogers EM. A prospective and retrospective look at the diffusion model. J Health Commun 2004; 9(Suppl 1): 13–9.

    OpenUrlCrossRefPubMedWeb of Science
27. Haider M, Kreps GL. Forty years of diffusion of innovations: utility and value in public health. J Health Commun 2004; 9(Suppl 1): 3–11.

    OpenUrlCrossRefPubMedWeb of Science
28. Berwick DM. Disseminating innovations in health care. JAMA 2003; 289: 1969–75.

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50: 1129–36.

    OpenUrlCrossRefPubMedWeb of Science
30. Romm FJ, Hulka BS, Kelly LW Jr. Internists’ perceptions and performance in office practice. South Med J 1980; 73: 405–10.

    OpenUrlPubMed
31. McPhee S, Richard R, Solkowitz S. Performance of cancer screening in a university general internal medicine practice: comparison with the 1980 American Cancer Society Guidelines. J Gen Int Med 1986; 1: 275–81.

    OpenUrlPubMedWeb of Science
32. Wu L, Ashton C. Chart review. A need for reappraisal. Eval Health Prof 1997; 20: 146–63.

    OpenUrlAbstract/FREE Full Text
33. ↵
    Nelson H, Huffman L, Fu R, Harris E, Walker M, Bougatsos C. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Portland: Oregon Evidence-based Practice Center, Oregon Health & Science University; 2005: contract number 290–02-0024.